Pharma Managers Series – Healthcare Cost Effectiveness

Prof Michael Barry joins us on Wednesday 25th January, 2023 to discuss Healthcare Cost Effectiveness and will give an outline of the trends and observations in reimbursement across the industry along with policy updates from the NCPE. 

This will be an essential stakeholder briefing for anyone involved with market access, commercial or external relationship management aspects in their organisations. 

This event is now closed to bookings.  If you would like to join the waiting list, please contact us at info@thepmi.com 

Prof. Michael Barry, Director – National Centre for Pharmacoeconomics 

Prof. Michael Barry is a Consultant Clinical Pharmacologist and Head of the Department of Pharmacology & Therapeutics at the University of Dublin, Trinity College. He is the clinical director of the National Centre for Pharmacoeconomics which conducts pharmacoeconomic evaluations on medicines prior to reimbursement under the Community Drugs schemes in Ireland.  He is Past-President (2010-2011) of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). He was a board member of the Health Information and Quality Authority (HIQA) and is a member of a number of National Committees on pricing and reimbursement of medicines. Prof. Barry chairs the New Drugs Committee and the Medication Safety Committee at St. James’s Hospital, Dublin. In 2013 he was appointed as Clinical Lead for the new HSE Medicines Management Programme. He is a fellow of the Royal College of Physicians in Ireland and is a specialty trainer for Pharmacology & Therapeutics. His research areas include the cost-effectiveness of high cost drugs including chemotherapeutic agents and biologic drugs, pricing and reimbursement and performance based risk sharing schemes. He has published widely on the cost-effectiveness of medicines in the Irish healthcare setting.

Sandra Redmond, Managing Director – Salutem Insights 

Sandra is a Health Economist and is currently Managing Director of Salutem Insights.  Following a Degree and Masters in Economics from UCD, she worked as a Researcher in UCD for 2 years, followed by 5 years as an Economic Consultant in Dublin and Australia, followed by 13 years in Market Access in GSK.  She conducted her first of many HTAs on a new treatment for HER2+ breast cancer in GSK in 2017 and has been fascinated by this field of economics since then. She joined Salutem Insights in 2018 where she and her team provide expert economic consultancy advice to industry. 

Salutem Insights are an Irish-based market access consultancy company that specialises in conducting all types of economic analysis including HTAs, burden of illness studies, systematic reviews and quality checks on HTAs. Salutem Insights also provides training to industry on health economics, economic modelling and on ensuring that the high standards required for completion of HTA submissions are met.

This event is proudly supported by: 

THIS EVENT IS NOW FULLY BOOKED